These results suggested that the increased expression of GH, GHRH, and ERβ by DCE-2.5 or DCE-5 might be associated with enhanced RAS signaling and positively impact human health and that the marked reductions observed in the expression of HER1, HER2, and IGFIIR after DCE-2.5 or DCE-5 treatment might be useful for the treatment of different human diseases, such as breast cancer and diabetes. Here, GHRH is linked to breast cancer.